Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dignitana AB's Brain Cool AB and University of Edinburgh Announce Phase One Clinical Trial


Monday, 4 Mar 2013 04:00am EST 

Dignitana AB announced that Brain Cool AB, its wholly-owned subsidiary, announced on March 4, 2013 that its new medical device for therapeutic brain cooling is being tested in a clinical trial at the University of Edinburgh. In this University of Edinburgh clinical trial, the device is being tested on healthy volunteers to measure efficacy of brain cooling rates. Brain Cool uses a patented cooling method developed by Dignitana, the maker of the DigniCap System for the prevention of chemotherapy-related hair loss. The technology used in the new Brain Cool System allows cooling of the neck, which helps to speed perfusion and cooling of blood before it reaches the brain-a critical intervention for patients suffering from stroke. Therapeutic hypothermia, or cooling, lowers a patient's body temperature to help reduce the risk of injury to the brain following a period of insufficient blood flow due to an ischemic event such as cardiac arrest, stroke, traumatic brain injury or neonatal asphyxia. Results from previous pilot studies suggest that even a small reduction of the brain temperature could be beneficial in treating stroke patients, and may even contribute to significantly reduced mortality rates and improved life for stroke survivors. Unlike other therapies, Brain Cool offers flexibility and ease of use for both patient and clinician. An advanced Brain Cool model that can be easily transported is in development in addition to the standard Brain Cool System available. 

Company Quote

10.7
0.4 +3.88%
24 Oct 2014